Clinical trials: Stage II and III
Melanoma
Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma
This is a multicenter, randomized, double-blind, parallel-group, 2 treatment group, repeated dose study to compare the PK, efficacy, safety, and immunogenicity of AVT32-DRL_PB (proposed Keytruda® biosimilar) versus Keytruda…
- Trial name
- NCT07475572
- Testing
- AVT32-DRL_PB, Keytruda
- Where
- Ukraine
- Volunteers
- 120 people
- Sponsor
- Alvotech Swiss AG
HER2-positive Breast Cancer
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
The purpose of this study is to assess the efficacy and safety of RO7771950 in combination with trastuzumab and capecitabine, compared to tucatinib in combination with trastuzumab and capecitabine.
- Trial name
- BREnnA (NCT07413939)
- Testing
- RO7771950, Tucatinib, Trastuzumab
- Where
- 206 sites in United States, Argentina and 23 more
- Volunteers
- 650 people
- Sponsor
- Hoffmann-La Roche
Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition
Beta Alethine in Treating Patients With Myeloma
RATIONALE: Biological therapies such as beta alethine use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00006466
- Testing
- beta alethine
- Where
- 3 sites in United States
- Sponsor
- LifeTime Pharmaceuticals
Squamous Cell Carcinoma of the Oral Cavity
IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity
The purpose of this study is to determine whether a pre-operative regimen of the study drug, IRX-2, a human cell-derived biologic with multiple active cytokine components, plus a single dose of cyclophosphamide, followed by 21…
- Trial name
- INSPIRE (NCT02609386)
- Testing
- IRX-2, Cyclophosphamide, Indomethacin
- Where
- 22 sites in United States, Brazil and 2 more
- Volunteers
- 105 people
- Sponsor
- Brooklyn ImmunoTherapeutics, LLC
Sedation
Safety, Efficacy and Pharmacokinetic Study of Dexmedetomidine in Pediatrics Ages ≥28 Weeks to ≤44 Weeks Gestational Age
The purpose of this study is to investigate the safety, efficacy and pharmacokinetics (PK) of dexmedetomidine (DEX) at 3 different dose levels in infants, ages ≥28 weeks to ≤44 weeks gestational age, administered as a loading…
- Trial name
- NCT01159262
- Testing
- Midazolam, Fentanyl/Morphine, Dexmedetomidine
- Where
- 18 sites in United States, Guatemala
- Volunteers
- 36 people
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Allergic Rhinoconjunctivitis
Long-term Efficacy and Safety Study With Oralgen Grass Pollen
This study is designed to give additional information on the efficacy, safety and local effects (tolerability) of a dose of sublingual immunotherapy administered once a day, during a second grass pollen season.
- Trial name
- NCT00824447
- Testing
- Oralgen
- Where
- 39 sites in Bulgaria, Czechia and 5 more
- Volunteers
- 356 people
- Sponsor
- Artu Biologicals
Primary Insomnia
A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia (Study 190-126)
The purpose of this study is to investigate and evaluate the efficacy of Eszopiclone in Japanese participants with primary insomnia.
- Trial name
- NCT00770510
- Testing
- Eszopiclone 1 mg, Eszopiclone 2 mg, Eszopiclone 3 mg
- Where
- 20 sites in Japan
- Volunteers
- 192 people
- Sponsor
- Eisai Co., Ltd.
Drug/Agent Toxicity by Tissue/Organ, Pancreatic Cancer
Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more tumor cells.
- Trial name
- NCT00024427
- Testing
- fluorouracil, gemcitabine hydrochloride, triacetyluridine
- Where
- 29 sites in United States, Canada
- Volunteers
- 250 people
- Sponsor
- Wellstat Therapeutics
Allergic Rhinoconjunctivitis
Efficacy and Safety of Grass Pollen Sublingual Immunotherapy
The study is assessing efficacy and safety of three different dosage regimens of grass pollen sublingual immunotherapy in adult patients suffering from grass pollen related rhinoconjunctivitis.
- Trial name
- NCT00567346
- Testing
- Oralgen, grass pollen extract
- Where
- 40 sites in Bulgaria, Czechia and 5 more
- Volunteers
- 605 people
- Sponsor
- Artu Biologicals
Kidney Injury
The NGAL Test™ As An Aid in the Risk Assessment for AKI Stage II and III in an Intensive Care Population
The NGAL TestTM is a particle-enhanced turbidimetric immunoassay for the quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human EDTA plasma for testing on automated clinical chemistry analyzer.
- Trial name
- NCT03057457
- Testing
- NGAL Test
- Where
- 2 sites in United States
- Volunteers
- 530 people
- Sponsor
- BioPorto Diagnostics
Metastatic Prostate Cancer, Lung Cancer
Cannabis Oil and Radiation Therapy for the Management of Pain
In this innovative approach seeking effective therapeutic strategies, the investigators are proposing to test the effectiveness of medical cannabis oil as an adjunct to palliative Radiation Therapy (RT) and Best Supportive Care…
- Conditions
- Metastatic Prostate Cancer, Lung Cancer, Breast Cancer
- Trial name
- NCT03763851
- Testing
- Active PPP005, Radiotherapy
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Tetra Bio-Pharma
Radiation-induced Lung Injury, Immune-related Pneumonia
Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia
Radiation-induced lung injury (RILI) is one of the most common thoracic-radiotherapy complications, with an incidence as high as 31.4 %.
- Trial name
- NCT07388680
- Testing
- Pirfenidone Capsules （400 mg）, Pirfenidone Capsules（600mg）, Pirfenidone Capsules（0mg）
- Where
- 36 sites in China
- Volunteers
- 298 people
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Lymphoma
BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase I/II trial to study the effectiveness BCX-1777 in treating patients who have refractory cutaneous…
- Trial name
- NCT00061880
- Testing
- forodesine hydrochloride
- Where
- 3 sites in United States
- Sponsor
- BioCryst Pharmaceuticals
Covid19
VIR-7831 for the Early Treatment of COVID-19 in Outpatients
This is a phase 2/3 study in which subjects with coronavirus disease 2019 (COVID-19) will receive VIR-7831 or placebo and will be assessed for safety, tolerability, efficacy, and pharmacokinetics.
- Trial name
- COMET-ICE (NCT04545060)
- Testing
- VIR-7831 (sotrovimab)
- Where
- 91 sites in United States, Austria and 5 more
- Volunteers
- 1,057 people
- Sponsor
- Vir Biotechnology, Inc.
T2DM
Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin
Phase 3 study to assess the Efficacy and Safety of CT-L03-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Empagliflozin Combination Therapy.
- Trial name
- CT-L03 (NCT06571591)
- Testing
- CT-L03 Group 1, CT-L03 Group 2, Empagliflozin
- Where
- South Korea
- Volunteers
- 606 people
- Sponsor
- Celltrion
Ankylosing Spondylitis
Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis
The purpose of this study is to assess efficacy, safety, pharmacokinetics and immunogenicity of subcutaneous SHR-1314 in patients with active ankylosing spondylitis
- Trial name
- NCT04840485
- Testing
- SHR-1314
- Where
- China
- Volunteers
- 548 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. IM-862 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood…
- Trial name
- NCT00017303
- Testing
- carboplatin, oglufanide disodium, paclitaxel
- Where
- 19 sites in United States
- Sponsor
- Cytran
Allergic Rhinitis
Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis
The purpose of this study is to assess the efficacy of two doses of sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily over a period of 12 months compared to placebo, for reduction of allergic…
- Trial name
- NCT00674700
- Testing
- 300 IR house dust mites allergen extract tablet, 500 IR house dust mites allergen extract tablet
- Volunteers
- 509 people
- Sponsor
- Stallergenes Greer
GBM
Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Grade IV GBM Patients
The purpose of phase II/III study: Determining the Overall Survival（OS）of Chlorogenic acid for injection comparing to in the advanced Glioblastoma Patients through study completion（an average of 18 months）after the first dose of…
- Trial name
- NCT03758014
- Testing
- Chlorogenic acid for Injection, Lomustine
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd
Melanoma
Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
The purpose of this clinical research study is to compare the best overall response rate (BORR)(as per modified WHO criteria) in patients with previously treated, therapy-refractory, or -intolerant, Stage III (unresectable) or…
- Trial name
- NCT00289640
- Testing
- ipilimumab (MDX-010, BMS-734016), Ipilimumab
- Where
- 62 sites in United States, Australia and 8 more
- Volunteers
- 210 people
- Sponsor
- Bristol-Myers Squibb